PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1880633
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1880633
The global safety pen needles market is witnessing consistent growth, driven by rising diabetes prevalence, expansion of home healthcare, and increasing preference for safe and convenient insulin delivery devices. The market was valued at USD 722.4 million in 2024, supported by the growing global burden of diabetes and high usage of insulin pens for chronic disease management. By 2025, the market is projected to reach USD 768.0 million, and by 2032, it is expected to expand significantly to USD 1,270.1 million, reflecting a CAGR of 7.5% during the forecast period. North America remained the dominant region in 2024, holding 42.44% of the global market share.
Safety pen needles are sterile, single-use devices engineered with protective mechanisms such as needle guards and shields to prevent accidental needlestick injuries. Their increasing adoption in clinical and home settings is largely attributed to their convenience, safety features, and compatibility with widely used insulin pens. Major companies such as Embecta Corp., Cardinal Health, and MTD Medical Technology and Devices continue to invest in technological upgrades, partnerships, and new product rollouts to strengthen their global presence.
Market Dynamics
Market Drivers
The sharp rise in diabetes prevalence remains the primary driver of market growth. The IDF Diabetes Atlas (2025) reports that 11.1% of adults aged 20-79 years are currently living with diabetes, highlighting the escalating demand for insulin therapy. Coupled with sedentary lifestyles, obesity, and rapid urbanization, the number of insulin users continues to grow worldwide. As patients and healthcare professionals seek safer injection methods, safety pen needles are increasingly preferred over standard pen needles and traditional syringes.
Market Restraints
The introduction of advanced alternative drug delivery technologies poses a significant challenge to market expansion. Innovations in needle-free systems-such as intranasal delivery and jet injectors-are gaining interest among patients and clinicians. In November 2024, Sol-Millennium Medical Group launched Insujet, a needle-free insulin delivery device in the U.S., representing a shift toward non-invasive drug delivery that may limit demand for safety pen needles in the coming years.
Market Opportunities
Home healthcare is emerging as one of the fastest-growing opportunity areas. According to NCBI (2023), around 60% of global insulin users prefer insulin pens for self-administration. The elderly population, in particular, benefits from the ease and safety of pen needles. Expanding remote patient care, personalized treatment plans, and availability of compact pen designs further support adoption. Emerging markets across Asia Pacific and Latin America are experiencing rapid increases in home-based diabetes management, presenting considerable untapped growth potential.
Market Challenges
The high cost of safety pen needles remains a barrier to widespread adoption. As noted by the NHS (June 2025), safety pen needles can be up to 8 times more expensive than standard needles and are often not reimbursed in developing regions. Limited affordability continues to restrict their use in China, India, and other low-income markets.
Market Trends
Manufacturers are integrating advanced safety mechanisms with ultra-thin needle technology to improve comfort and adherence. Pen needles with 4mm length and 32-34 gauge structures reduce injection pain and enhance patient experience. Auto-retraction, passive shielding, and hidden-needle systems are increasingly being incorporated. Furthermore, collaborations between medical device makers and pharmaceutical companies are expanding the availability of safety-enhanced injection systems for insulin and GLP-1 agonists.
North America led the market in 2024 with a valuation of USD 306.6 million, supported by high diabetes incidence and strong product availability. Increased regulatory approvals for growth hormone therapies in the U.S. also support demand. Europe held the second-largest share, with rising prescription volumes and growing awareness campaigns. Asia Pacific is projected to record the fastest CAGR, fueled by the region's high diabetes prevalence and new distribution partnerships. Latin America and Middle East & Africa are experiencing steady momentum, driven by rising obesity levels and expanding access to advanced drug delivery devices.
Conclusion
With market value rising from USD 722.4 million in 2024 to USD 1,270.1 million by 2032, the safety pen needles market demonstrates strong long-term growth potential. Demand will continue to be shaped by diabetes prevalence, home-care expansion, product innovation, and strategic industry partnerships, even as needle-free technologies create competitive pressure.
Segmentation By Product Type, Drug Type, Disease Indication, Needle Size, Distribution Channel, and Region
By Product Type * Active Safety Pen Needles
By Drug Type * Insulin
By Disease Indication * Diabetes
By Needle Size * 4 mm
By Distribution Channel * Hospital Pharmacy
By Region * North America (By Product Type, Drug Type, Disease Indication, Needle Size, Distribution Channel, and Country/Sub-region)
U.S.
Canada
U.K.
Germany
France
Italy
Spain
Scandinavia
Rest of Europe
China
Japan
India
Australia
Southeast Asia
Rest of Asia Pacific
Brazil
Mexico
Rest of Latin America
GCC
South Africa
Middle East & Africa